Trial · NCT01121991
Results by group11
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 11 of 11
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Number of Metaphase II Oocytes Per Participant Who Underwent Ovum Pick up for Intra-cytoplasmic Sperm Injection (ICSI) | Recombinant Human-Luteinizing Hormone (Luveris) | 9.5 | Standard Deviation 4.2 | Metaphase II Oocytes | |
| Mean Number of Mature Oocytes Per Participant Who Underwent Ovum Pick up for In Vitro Fertilization (IVF) | Recombinant Human-Luteinizing Hormone (Luveris) | 7.5 | Standard Deviation 6.8 | oocytes | |
| Mean Number of Oocytes Retrieved Per Number of Follicles Aspirated on the Day of Ovum Pick up | Recombinant Human-Luteinizing Hormone (Luveris) | 0.9 | Standard Deviation 0.2 | oocytes per aspirated follicle | |
| Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies | Recombinant Human-Luteinizing Hormone (Luveris) | Participants with confirmed biochemical pregnancy | 22 | participants | |
| Number of Participants With Confirmed Pregnancies: Biochemical Pregnancies and Clinical Pregnancies | Recombinant Human-Luteinizing Hormone (Luveris) | Participants with confirmed clinical pregnancy | 14 | participants | |
| Number of Participants With Multiple Pregnancies | Recombinant Human-Luteinizing Hormone (Luveris) | 4 | participants | ||
| Number of Live Births | Recombinant Human-Luteinizing Hormone (Luveris) | 13 | Live births | ||
| Pregnancy Loss Per Clinical Pregnancy | Recombinant Human-Luteinizing Hormone (Luveris) | 7.14 | Percentage of pregnancy loss | ||
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation. | Recombinant Human-Luteinizing Hormone (Luveris) | TEAEs | 15 | Number of participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation. | Recombinant Human-Luteinizing Hormone (Luveris) | SAEs | 3 | Number of participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Drug Discontinuation. | Recombinant Human-Luteinizing Hormone (Luveris) | Discontinuation due to AEs | 0 | Number of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01121991/results